Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen. ... Keytruda. Package insert. Merck; 2025. Accessed June 13, 2025.

Learn about cost, uses, and more of Keytruda (pembrolizumab). It's a prescription drug that treats certain cancers in adults and some children.

Keytruda was also studied in people who had NSCLC that was positive for PDL-1 and progressed after chemotherapy. People in this trial got either Keytruda 2 mg/kg, Keytruda 10 mg/kg, or chemotherapy.

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption ...

RAHWAY, N.J., May 31, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab) plus Trodelvy® (sacituzumab govitecan-hziy ...

RAHWAY, N.J., April 27, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.